Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
33
BMY Quote, Financials, Valuation and Earnings
Last price:
$57.83
Seasonality move
:
0.53%
Day range:
$57.01 - $57.77
52-week range:
$39.35 - $61.08
Dividend yield:
4.16%
P/E ratio:
--
P/S ratio:
2.47x
P/B ratio:
6.83x
Volume:
3.7M
Avg. volume:
11.7M
1-year change:
10.46%
Market cap:
$117.1B
Revenue:
$45B
EPS (TTM):
-$3.59
Analysts' Opinion
-
Consensus RatingBristol-Myers Squibb has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 17 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $60.91, Bristol-Myers Squibb has an estimated upside of 5.45% from its current price of $57.76.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $39.00 representing 100% downside risk from its current price of $57.76.
Fair Value
-
According to the consensus of 22 analysts, Bristol-Myers Squibb has 5.45% upside to fair value with a price target of $60.91 per share.
BMY vs. S&P 500
-
Over the past 5 trading days, Bristol-Myers Squibb has underperformed the S&P 500 by -2.68% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bristol-Myers Squibb does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bristol-Myers Squibb has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Bristol-Myers Squibb reported revenues of $11.9B.
Earnings Growth
-
Bristol-Myers Squibb earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Bristol-Myers Squibb reported earnings per share of $0.60.
Enterprise value:
158.9B
EV / Invested capital:
2.37x
Price / LTM sales:
2.47x
EV / EBIT:
--
EV / Revenue:
3.35x
PEG ratio (5yr expected):
--
EV / Free cash flow:
11.51x
Price / Operating cash flow:
8.49x
Enterprise value / EBITDA:
31.33x
Gross Profit (TTM):
$35.5B
Return On Assets:
-7.66%
Net Income Margin (TTM):
-15.3%
Return On Equity:
-33.18%
Return On Invested Capital:
-10.53%
Operating Margin:
18.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $46.7B | $44.9B | $47.4B | $11B | $11.9B | |
| Gross Profit | $36.8B | $34.4B | $35.5B | $8.5B | $8.9B | |
| Operating Income | $9.8B | $8B | $7.3B | $2B | $2.2B | |
| EBITDA | $19.3B | $19.6B | $5.1B | $4.9B | $4.8B | |
| Diluted EPS | $3.07 | $3.94 | -$3.59 | $0.93 | $0.60 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $34.3B | $31.4B | $26.8B | $27.6B | $28.1B | |
| Total Assets | $125.5B | $110.9B | $98.2B | $91.3B | $93.7B | |
| Current Liabilities | $20.5B | $21.5B | $18.9B | $23.5B | $22.6B | |
| Total Liabilities | $75.3B | $73.6B | $65.5B | $62.2B | $76.5B | |
| Total Equity | $50.2B | $37.3B | $32.7B | $29.1B | $17.2B | |
| Total Debt | $44.9B | $44.7B | $39.1B | $37.6B | $49.8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $13.8B | $12.9B | $15B | $4.8B | $5.6B | |
| Cash From Investing | -$1.9B | $264M | -$22.5B | -$410M | -$219M | |
| Cash From Financing | -$17.7B | -$13.6B | $7.7B | -$5.2B | -$3.9B | |
| Free Cash Flow | $12.7B | $11.7B | $13.8B | $4.4B | $5.3B | |
BMY
Sector
Market Cap
$117.1B
$46.1M
Price % of 52-Week High
94.57%
46.02%
Dividend Yield
4.16%
0%
Shareholder Yield
2.28%
-0.6%
1-Year Price Total Return
10.46%
-30.52%
Beta (5-Year)
0.454
0.772
Dividend yield:
4.16%
Annualized payout:
$2.28
Payout ratio:
-66.2%
Growth streak:
2 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$56.89
200-day SMA
Buy
Level
$49.27
Bollinger Bands (100)
Buy
Level
49.06 - 57
Chaikin Money Flow
Buy
Level
685.7M
20-day SMA
Sell
Level
$57.87
Relative Strength Index (RSI14)
Buy
Level
53.14
ADX Line
Sell
Level
10.63
Williams %R
Neutral
Level
-42.3729
50-day SMA
Buy
Level
$56.33
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
440.8M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.2966)
Sell
CA Score
(Annual)
Level (-0.6792)
Buy
Beneish M-Score
(Annual)
Level (-2.7233)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-0.9398)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Stock Forecast FAQ
In the current month, BMY has received 4 Buy ratings 17 Hold ratings, and 1 Sell ratings. The BMY average analyst price target in the past 3 months is $60.91.
-
Where Will Bristol-Myers Squibb Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bristol-Myers Squibb share price will rise to $60.91 per share over the next 12 months.
-
What Do Analysts Say About Bristol-Myers Squibb?
Analysts are divided on their view about Bristol-Myers Squibb share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bristol-Myers Squibb is a Sell and believe this share price will drop from its current level to $39.00.
-
What Is Bristol-Myers Squibb's Price Target?
The price target for Bristol-Myers Squibb over the next 1-year time period is forecast to be $60.91 according to 22 Wall Street analysts, 4 of them rate the stock a Buy, 1 rates the stock a Sell, and 17 analysts rate the stock a Hold.
-
Is BMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bristol-Myers Squibb is a Hold. 17 of 22 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BMY?
You can purchase shares of Bristol-Myers Squibb via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bristol-Myers Squibb shares.
-
What Is The Bristol-Myers Squibb Share Price Today?
Bristol-Myers Squibb was last trading at $57.83 per share. This represents the most recent stock quote for Bristol-Myers Squibb. Yesterday, Bristol-Myers Squibb closed at $57.76 per share.
-
How To Buy Bristol-Myers Squibb Stock Online?
In order to purchase Bristol-Myers Squibb stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 26
Power Solutions International [PSIX] is down 0.55% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.38% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 0.65% over the past day.
